Last update Aug. 18, 2021
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Mexazolam is also known as
Mexazolam in other languages or writings:
Variable | Value | Unit |
---|---|---|
Molecular weight | 363 | daltons |
Protein Binding | 90 | % |
VD | 2.14 | l/Kg |
pKa | 3.76 | - |
Tmax | 1 - 2 | hours |
T½ | 130 - 200 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Ultra-long-acting benzodiazepine, with properties similar to diazepam but with an even longer action (T1/2 > 130 h: Bial 2000).
Used in the treatment of anxiety.
Oral administration three times per day.
At the date of the last update, the authors found no published data regarding breastfeeding.
Its pharmacokinetic data does not allow a good prediction of the possible passage into breast milk, because while its high percentage of protein binding, large volume of distribution and acid pKa would prevent it, its very long half-life would facilitate it.
Safer known alternatives are preferable.
Product with very few bibliographic references and marketed in very few countries.
Occasional and low-dose use of benzodiazepines is compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
Choose short-acting benzodiazepines and use the lowest effective dose (Rowe 2013), especially during the neonatal period and in prematurity, as they can accumulate in the infant during chronic use (Sachs 2013, Amir 2011).
It is advisable to monitor drowsiness and adequate feeding of the infant.
Bed-sharing with the baby is not recommended if this medicine is being taken due to increased risk of suffocation or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).